Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyCUDC-907
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- CUDC-907
- Accession Number
- DB11891
- Type
- Small Molecule
- Groups
- Investigational
- Description
CUDC-907 has been used in trials studying the treatment of Lymphoma, Solid Tumors, BREAST CANCER, Multiple Myeloma, and NUT Midline Carcinoma, among others.
- Structure
- Synonyms
- Not Available
- External IDs
- CUDC907
- Categories
- UNII
- 3S9RX35S5X
- CAS number
- 1339928-25-4
- Weight
- Average: 508.56
Monoisotopic: 508.164122459 - Chemical Formula
- C23H24N8O4S
- InChI Key
- JOWXJLIFIIOYMS-UHFFFAOYSA-N
- InChI
- InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)
- IUPAC Name
- N-hydroxy-2-({[2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl}(methyl)amino)pyrimidine-5-carboxamide
- SMILES
- COC1=CC=C(C=N1)C1=NC(N2CCOCC2)=C2SC(CN(C)C3=NC=C(C=N3)C(=O)NO)=CC2=N1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbexinostat The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Abexinostat. Acebutolol The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Acebutolol. Aceprometazine The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Aceprometazine. Acetyldigoxin The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Acetyldigoxin. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with CUDC-907. Adenosine The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Adenosine. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with CUDC-907. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with CUDC-907. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with CUDC-907. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with CUDC-907. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Compound
- 54575456
- PubChem Substance
- 347828226
- ChemSpider
- 29314960
- BindingDB
- 50188961
- ChEMBL
- CHEMBL3622533
- Wikipedia
- Phosphoinositide_3-kinase_inhibitor
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0153 mg/mL ALOGPS logP 2.59 ALOGPS logP 2.78 ChemAxon logS -4.5 ALOGPS pKa (Strongest Acidic) 9.24 ChemAxon pKa (Strongest Basic) 3.36 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 11 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 138.72 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 145.82 m3·mol-1 ChemAxon Polarizability 53.01 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Pyridinylpyrimidines
- Alternative Parents
- Thienopyrimidines / Pyrimidinecarboxamides / 2,3,5-trisubstituted thiophenes / Dialkylarylamines / Alkyl aryl ethers / Aminopyrimidines and derivatives / Pyridines and derivatives / Morpholines / Imidolactams / Heteroaromatic compounds show 6 more
- Substituents
- Pyridinylpyrimidine / Thienopyrimidine / Pyrimidine-5-carboxylic acid or derivatives / Pyrimidinecarboxamide / Dialkylarylamine / 2,3,5-trisubstituted thiophene / Alkyl aryl ether / Aminopyrimidine / Morpholine / Oxazinane show 18 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Drug created on October 20, 2016 14:57 / Updated on December 02, 2019 09:13